Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT-HD: Ensitrelvir in COVID-19 Patients Undergoing Hemodialysis
jRCTs071240069Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ensitrelvir in coronavirus disease 2019 (COVID-19), sponsored by Shionogi & Co., Ltd. Primary endpoints: Ensitrelvir concentration in plasma and Ensitrelvir amount in dialysis recovery fluid and dialysis clearance. Started Dec 2024; status: completed.
02
Drugs
ensitrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCTs071240069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071240069.